within Pharmacolibrary.Drugs.ATC.D;

model D11AH01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 6.333333333333333e-07,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00152,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.03283333333333333,
    Tlag           = 27.6,            
    Vdp             = 0.0008100000000000001,
    k12             = 0.038,
    k21             = 0.038
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D11AH01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tacrolimus is a calcineurin inhibitor with potent immunosuppressive properties. It is primarily used to prevent organ transplant rejection and to treat autoimmune diseases such as atopic dermatitis. It is approved for clinical use worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model for adult healthy volunteers and transplant recipients; both sexes. Oral administration; data primarily referenced from studies on liver and kidney transplant patients.</p><h4>References</h4><ol><li><p>Venkataramanan, R, et al., &amp; Starzl, T (1995). Clinical pharmacokinetics of tacrolimus. <i>Clinical pharmacokinetics</i> 29(6) 404–430. DOI:<a href=\"https://doi.org/10.2165/00003088-199529060-00003\">10.2165/00003088-199529060-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8787947/\">https://pubmed.ncbi.nlm.nih.gov/8787947</a></p></li><li><p>Martial, LC, et al., &amp; Moes, DJAR (2021). Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. <i>British journal of clinical pharmacology</i> 87(11) 4262–4272. DOI:<a href=\"https://doi.org/10.1111/bcp.14842\">10.1111/bcp.14842</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33786892/\">https://pubmed.ncbi.nlm.nih.gov/33786892</a></p></li><li><p>Lee, KW, et al., &amp; Kim, SJ (2019). Reduced variability in tacrolimus pharmacokinetics following intramuscular injection compared to oral administration in cynomolgus monkeys: Investigating optimal dosing regimens. <i>Journal of pharmacological sciences</i> 139(2) 65–71. DOI:<a href=\"https://doi.org/10.1016/j.jphs.2018.05.013\">10.1016/j.jphs.2018.05.013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30573325/\">https://pubmed.ncbi.nlm.nih.gov/30573325</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D11AH01;
